top of page
Search

Guidance on Metastasis-Free Survival as an Endpoint - Prostate Cancer trials – USFDA

USFDA on 06-July-2021, finalized guidance on the use of metastasis-free survival (MFS) as an endpoint in clinical trials for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Nonmetastatic castration-resistant prostate cancer (nmCRPC) is defined as "a rising prostate-specific antigen concentration, despite castrate levels of testosterone with ongoing androgen-deprivation therapy or orchiectomy, and no detectable metastases by conventional imaging".


The length of time from the start of treatment for cancer that a patient is still alive and cancer has not spread to other parts of the body. In a clinical trial, measuring metastasis-free survival is one way to see how well a new treatment works. Also called MFS.

This guidance provides recommendations to sponsors about using metastasis-free survival (MFS) as an endpoint in clinical trials for nonmetastatic castration-resistant prostate cancer (nmCRPC) development programs for drug or biological products regulated by FDA.

The guidance covers recommendations for sponsors on general trial design considerations, imaging considerations, and considerations related to the interpretation of trial results and analyses of MFS.

Comments

I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page